BioScrip, Inc. (NASDAQ:BIOS) Director Coliseum Capital Management, L sold 2,846,941 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $2.93, for a total value of $8,341,537.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Coliseum Capital Management, L also recently made the following trade(s):

  • On Thursday, August 17th, Coliseum Capital Management, L sold 886,478 shares of BioScrip stock. The shares were sold at an average price of $3.08, for a total value of $2,730,352.24.

BioScrip, Inc. (BIOS) opened at 2.71 on Friday. The company’s market cap is $345.46 million. The company’s 50 day moving average price is $2.91 and its 200-day moving average price is $2.22. BioScrip, Inc. has a one year low of $0.98 and a one year high of $3.43.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $218.11 million during the quarter, compared to analysts’ expectations of $220.05 million. During the same period in the prior year, the company earned ($0.14) earnings per share. The business’s revenue was down 6.2% compared to the same quarter last year. On average, analysts forecast that BioScrip, Inc. will post ($0.55) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/09/coliseum-capital-management-l-sells-2846941-shares-of-bioscrip-inc-bios-stock.html.

Several hedge funds have recently modified their holdings of the stock. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of BioScrip by 248.4% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock worth $41,298,000 after acquiring an additional 10,845,410 shares during the last quarter. FMR LLC lifted its stake in shares of BioScrip by 10.8% during the 2nd quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after acquiring an additional 520,231 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of BioScrip by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after acquiring an additional 146,980 shares during the last quarter. Wynnefield Capital Inc. lifted its stake in shares of BioScrip by 2.7% during the 1st quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock worth $6,460,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Alta Fundamental Advisers LLC lifted its stake in shares of BioScrip by 36.9% during the 2nd quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after acquiring an additional 818,000 shares during the last quarter. 84.15% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently commented on BIOS. ValuEngine downgraded BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. SunTrust Banks, Inc. upgraded BioScrip from a “hold” rating to a “buy” rating and upped their target price for the company from $3.25 to $3.75 in a report on Thursday, August 10th. Finally, Jefferies Group LLC restated a “buy” rating and set a $4.00 target price (up previously from $3.00) on shares of BioScrip in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.75.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.